CN103857672B - 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 - Google Patents

用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 Download PDF

Info

Publication number
CN103857672B
CN103857672B CN201280049302.7A CN201280049302A CN103857672B CN 103857672 B CN103857672 B CN 103857672B CN 201280049302 A CN201280049302 A CN 201280049302A CN 103857672 B CN103857672 B CN 103857672B
Authority
CN
China
Prior art keywords
compound
formula
mixture
production
alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280049302.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103857672A (zh
Inventor
房极赞
文荣沪
张永佶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103857672(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Priority to CN201811593540.XA priority Critical patent/CN110003174A/zh
Publication of CN103857672A publication Critical patent/CN103857672A/zh
Application granted granted Critical
Publication of CN103857672B publication Critical patent/CN103857672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280049302.7A 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 Active CN103857672B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811593540.XA CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
KR10-2011-0101422 2011-10-05
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811593540.XA Division CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Publications (2)

Publication Number Publication Date
CN103857672A CN103857672A (zh) 2014-06-11
CN103857672B true CN103857672B (zh) 2018-11-30

Family

ID=48044309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280049302.7A Active CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
CN201811593540.XA Pending CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811593540.XA Pending CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Country Status (23)

Country Link
US (1) US8859767B2 (https=)
EP (2) EP3611172A1 (https=)
JP (1) JP5805880B2 (https=)
KR (1) KR101272613B1 (https=)
CN (2) CN103857672B (https=)
AU (1) AU2012319291B2 (https=)
BR (1) BR112014007718B1 (https=)
CA (1) CA2850055C (https=)
CY (1) CY1122758T1 (https=)
DK (1) DK2763981T3 (https=)
ES (1) ES2775197T3 (https=)
HR (1) HRP20200426T1 (https=)
HU (1) HUE048798T2 (https=)
IL (3) IL231911B (https=)
IN (1) IN2014DN03447A (https=)
LT (1) LT2763981T (https=)
MX (1) MX348815B (https=)
PL (1) PL2763981T3 (https=)
PT (1) PT2763981T (https=)
RS (1) RS60118B1 (https=)
RU (1) RU2563630C1 (https=)
SI (1) SI2763981T1 (https=)
WO (1) WO2013051883A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2016150340A1 (zh) 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
US20220064145A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
KR20120007059A (ko) * 2009-04-23 2012-01-19 아스트라제네카 아베 4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Also Published As

Publication number Publication date
ES2775197T3 (es) 2020-07-24
KR101272613B1 (ko) 2013-06-10
JP2014528444A (ja) 2014-10-27
PT2763981T (pt) 2020-03-25
BR112014007718B1 (pt) 2022-02-22
EP3611172A1 (en) 2020-02-19
BR112014007718A2 (pt) 2017-04-25
CN103857672A (zh) 2014-06-11
RS60118B1 (sr) 2020-05-29
AU2012319291B2 (en) 2016-03-31
IN2014DN03447A (https=) 2015-06-26
KR20130037079A (ko) 2013-04-15
EP2763981A2 (en) 2014-08-13
MX348815B (es) 2017-06-30
CY1122758T1 (el) 2021-03-12
EP2763981B1 (en) 2020-01-08
RU2563630C1 (ru) 2015-09-20
LT2763981T (lt) 2020-05-25
SI2763981T1 (sl) 2020-07-31
CN110003174A (zh) 2019-07-12
CA2850055C (en) 2016-05-17
US8859767B2 (en) 2014-10-14
AU2012319291A1 (en) 2014-05-22
HRP20200426T1 (hr) 2020-09-04
IL259694A (en) 2018-07-31
EP2763981A4 (en) 2015-02-25
US20140275534A1 (en) 2014-09-18
PL2763981T3 (pl) 2020-08-10
WO2013051883A2 (en) 2013-04-11
CA2850055A1 (en) 2013-04-11
IL231911A0 (en) 2014-05-28
IL259694B (en) 2022-04-01
HUE048798T2 (hu) 2020-08-28
WO2013051883A3 (en) 2013-06-06
IL291738A (en) 2022-05-01
IL231911B (en) 2018-06-28
JP5805880B2 (ja) 2015-11-10
MX2014003959A (es) 2014-05-14
CA2850055E (en) 2013-04-11
DK2763981T3 (da) 2020-03-16

Similar Documents

Publication Publication Date Title
CN103857672B (zh) 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
CN103965120B (zh) 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
TW201904973A (zh) 作為mek抑制劑的類香豆素環類化合物及其應用
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
WO2015007249A1 (zh) N-烷基色胺酮衍生物及其制备方法和应用
CN102796079B (zh) 一种甲磺酸氟马替尼的制备方法
CN102149680A (zh) 含氮芳族杂环化合物
KR20200120177A (ko) 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민의 신규염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2006118231A1 (ja) シアノピリジン誘導体及びその医薬としての用途
HUE024989T2 (en) Azaindole derivatives as ABI and SRC protein kinase inhibitors
CN104981467B (zh) 制备l‑(4‑(4‑(3,4‑二氯‑2‑氟苯基氨基)‑7‑甲氧基喹唑啉‑6‑基氧)哌啶‑l‑基)丙‑2‑烯‑l‑酮的方法
WO2019170088A1 (zh) 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用
TWI714702B (zh) 一種吡啶衍生物類化合物的製備方法及其中間體和晶型
TW200531958A (en) Method for producing aminophenol compounds
CN112341344B (zh) 一种激酶抑制剂中间体的制备方法
CN118084871B (zh) 一种靶向降解c-Met蛋白的化合物及其制法和应用
HK40010388A (en) Preparation method for hydrochloride compound
KR102204267B1 (ko) 대체된 (r)-3-(4-메틸카바모일-3-플루오로페닐아미노)테트라하이드로퓨란-3-엔카르복실산(변이체) 및 이의 에스테르, 제조 방법 및 용도
TW201821408A (zh) 一種吡啶酮類衍生物的製備方法及其中間體
KR101116754B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 6-아미노-ν-하이드록시헥산아마이드 화합물 및 이의 제조방법
HK1196132B (zh) 用於制备1-(4-(4-(3，4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
HK1196132A (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
WO2022255399A1 (ja) Ｇ９ａ阻害剤
WO2020188833A1 (ja) ビアリールアミド誘導体の製造方法
CN105001205A (zh) 一种伊马替尼杂质d的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1196132

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant